NCT03798678View on ClinicalTrials.gov

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO

DRUG

Telaglenastat Hydrochloride

Given PO

Trial Locations (5)

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic in Rochester, Rochester

06520

Yale University, New Haven

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH